Skip to content

Surveillance of Healthcare-associated Infections & Antimicrobial Resistance

Surveillance of Healthcare-associated Infections & Antimicrobial Resistance

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05734391
Enrollment
1500
Registered
2023-02-21
Start date
2022-10-01
Completion date
2027-12-20
Last updated
2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antimicrobial Resistance

Brief summary

The aims of this project, called Surveillance of Healthcare-associated infections & Antimicrobial Resistance, or SHARE, are to 1) enhance laboratory capacity to detect emerging AMR patterns; 2) strengthen hospital epidemiology programs to use data to prevent, detect, and contain emerging AMR threats; 3) deploy study teams to answer critical public health surveillance questions, and 4) to build a national network of infection prevention and control (IPC) resources to prevent, detect, and contain emerging infectious disease threats

Detailed description

The World Health Organization (WHO) has declared antimicrobial resistance (AMR) one of the top 10 global public health threats facing humanity. AMR burden is higher in low-and-middle-income countries (LMICs) where, in recent decades, incidence and mortality from healthcare-associated infections (HAI) due to multidrug resistant organisms (MDRO) have dramatically increased. For example, neonatal sepsis is the third most common cause of neonatal deaths and multidrug-resistant Gram-negative bacteria are now the leading cause of sepsis among hospitalized neonates in south Asia and sub-Saharan Africa, including Botswana.1,2 One in three newborns with an MDRO bloodstream infection will die.3 In 2021, to respond to the global threat of AMR, U.S. Centers for Disease Control & Prevention (CDC) announced the launch of a global network of networks to tackle the problem of AMR and healthcare-associated infections (HAIs). The network, called Global Antimicrobial Resistance Laboratory and Response Network, solicited funding applications; in December of 2021, Botswana was announced as recipient of a 5-year cooperative agreement following the successful application for funding for a comprehensive AMR surveillance project. The project was developed by investigators from Botswana-UPenn Partnership (BUP) in collaboration with Botswana's Ministry of Health & Wellness (MOHW) and the University of Botswana (UB).

Interventions

DIAGNOSTIC_TESTRoutine Infection control

routine part of hospital IPC activities

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* hospital inpatient admission to participating wards.

Exclusion criteria

* diagnosis of a bleeding disorder * platelet counts of \<50,000 * diagnosis of coagulopathy * presence of active bleeding * inability to have a nares swab collected due to some other condition where nasal swabbing would be contraindicated * inability to have a rectal swab collected due to some other condition where rectal swabbing would be contraindicated

Design outcomes

Primary

MeasureTime frameDescription
Expertise12 monthsUltimately, the goal of the SHARE project is to assemble the expertise and infrastructure needed to build a resilient HAI/AMR surveillance system fully-incorporated into MOHW's surveillance activities. The project aims to build capacity, both material and knowledge, in existing laboratory and IPC teams to face the dynamic challenges posed by HAIs and AMR

Secondary

MeasureTime frameDescription
Feasibility and Surveillance12 monthsSHARE's Colonization Feasibility Study, will seek to assess the feasibility and surveillance potential of routine MDRO screening in hospitals, determining whether MDRO colonization can provide an early warning system for emerging AMR threats

Countries

Botswana, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026